Far-Reaching Effect of IPR Estoppel Dooms Invalidity Defense Based on Prior Art Product

Jan 29, 2020

Reading Time : 2 min

The case began in 2013 when Wasica filed a patent infringement suit against Schrader for allegedly infringing claims related to monitoring air pressure in tires. In response, Schrader filed petitions for IPR challenging the claims of the asserted patent. The district court stayed the case pending IPR resolution. Following a final written decision and appellate review by the Federal Circuit, several claims survived the IPR. The district court then lifted the stay, and Wasica proceeded on allegations of infringement of only one of the surviving patent claims. Schrader raised three obviousness defenses, each relying on a prior art product—namely, tire pressure sensors manufactured for the Chevrolet Corvette—in combination with a patent or a combination of patents and printed publications.

Wasica moved for summary judgment on all of Schrader’s obviousness defenses, arguing that Schrader was estopped under 35 U.S.C. § 315(e)(2) from asserting obviousness grounds that could have been raised in the IPR. Wasica argued that all of the patents and printed publications relied on by Schrader either were, or could have been, raised during the IPR. Wasica further contended that one of the printed publications disclosed all of the relevant features of the prior art product. Schrader countered that estoppel did not apply because the IPR statute does not allow challenges based on prior art products and that, as such, its obviousness defense could not have been raised in the IPR.

The district court agreed with Wasica. First, the court acknowledged the split among district courts regarding the scope of § 315(e)(2) estoppel. Next, the court explained that the IPR statute distinguishes between the grounds that may be raised (under § 102 and § 103) and the evidence that can be used to support those grounds (patents and printed publications). The court then found that the prior art product was “materially identical (i.e., disclose[d] the same claim elements)” to a printed publication that reasonably could have been raised in the IPR. Thus, the court ruled that the grounds reasonably could have been raised, and so Schrader’s obviousness defenses were estopped.

Practice Tip: Courts continue to wrestle with how to apply IPR estoppel under § 315(e)(2) to prior art products asserted in support of defenses raised under § 102 or § 103. Several decisions have construed estoppel narrowly and have held that it cannot be applied to prior art products, while other decisions have considered whether there are substantive differences between the prior art product and printed publication that would preclude the application of estoppel. This area of law continues to develop, but until the Federal Circuit rules on the issue, litigants should consider their strategies carefully. Patent owners who can file suit in more than one district should consider how the potential forums have applied estoppel to a prior art product in previous rulings. Accused infringers should consider whether pursuing an IPR may subsequently foreclose defenses that are based on a prior art product.

Wasica Fin. GmbH v. Schrader Int’l, Inc., 13-cv-01353 (D. Del. Jan. 14, 2020) (Stark, C.J.)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.